Within the ovarian cancer subset, camonsertib anti-tumor activity was observed in patients with BRCA1-altered tumors previously treated with PARPi or platinum therapy, most notably in a post-PARPi-treated patient with a germline BRCA1 alteration, despite the presence of reversion mutations. This evidence concerns the gene BRCA1 and ovarian cancer.